CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
OSSIX-Plusdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00639860
NCT00639860Phase 2Completed
CompareCT.gov

Clinical and Histological Evaluation of OSSIX-Plus Resorbable Collagen Membranes for Alveolar Ridge Preservation Following Exodontia

William Giannobile·interventional·Posted Mar 20, 2008·Updated Mar 31, 2016

In Brief

A Phase 2 clinical trial evaluating OSSIX-Plus for Alveolar Bone Loss and 2 related conditions. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate clinically, histologically and radiographically the healing of extraction sockets covered with a resorbable collagen membrane (OSSIX-Plus) 12 weeks following exodontia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlveolar Bone Loss, Loss of Teeth Due to Extraction, Edentulous Alveolar Ridge
CountriesUnited States
CollaboratorsJohnson & Johnson, OraPharma

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 20, 2008
Enrollment StartMar 1, 2008
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.3 years ago

Interventions

OSSIX-Plusdevice

resorbable collagen membrane